{"id":"W4405374307","doi":"10.1016/j.iotech.2024.100796","title":"168TiP A phase I dose escalation/expansion study of GSK5764227 (GSK’227), a B7-homolog 3 (B7-H3) protein targeted antibody-drug conjugate (ADC), in patients with advanced solid tumours","year":2024,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Medical Imaging Techniques and Applications","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Ottawa Hospital","funders":"Institut National Du Cancer; Eisai; Fondation ARC pour la Recherche sur le Cancer; Seagen; Astellas Pharma; NuCana; Sanofi; Exelixis; BeiGene; Amgen; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Conjugate; Antibody-drug conjugate; Antibody; Medicine; Drug; Cancer research; Monoclonal antibody; Pharmacology; Immunology; Mathematics","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005149296,0.0004168155,0.001095304,0.001123495,0.0001243392,0.00001553169,0.000449987,0.0005295505,0.0001122152],"category_scores_gemma":[0.0003309491,0.0003381351,0.00009431264,0.001775859,0.0008693777,0.0001607806,0.000267512,0.001109316,0.00002586173],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003092317,"about_ca_system_score_gemma":0.0003833745,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001451803,"about_ca_topic_score_gemma":0.00006412491,"domain_scores_codex":[0.996824,0.0001737563,0.001104057,0.0008666466,0.0003810858,0.000650473],"domain_scores_gemma":[0.9980264,0.0001439881,0.000362492,0.0009945215,0.0003392069,0.0001334215],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.004772998,0.02611073,0.1237507,0.0004617145,0.0006013653,0.001206282,0.002479078,0.00002445996,0.7265956,0.00224207,0.002275189,0.1094798],"study_design_scores_gemma":[0.1813253,0.1309329,0.1968981,0.00891383,0.0026623,0.001108995,0.01155141,0.01288767,0.3773166,0.01471587,0.05724023,0.004446801],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9866242,0.0005820451,0.0009780247,0.005537336,0.0001763977,0.004834861,0.0000310532,0.001057795,0.0001782863],"genre_scores_gemma":[0.9902908,0.00007149248,0.007647209,0.0001694351,0.00003089284,0.001360498,0.0002112552,0.00007657285,0.0001418641],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.349279,"threshold_uncertainty_score":0.9999071,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.007515845738382482,"score_gpt":0.342843778635392,"score_spread":0.3353279328970095,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}